Activity Description

According to the American Cancer Society, Colorectal cancer (CRC) is the third
most common cancer diagnosis in the United States. It is also the third leading cause
of cancer deaths. Early detection of CRC is a major key to survival and cure. This
educational activity will provide an overview of the epidemiology, risk factors, pathology,
and staging of CRC. Common treatments used for CRC will be reviewed along with a discussion
of adverse effects and recommended monitoring. Strategies to improve the compliance
and adherence in CRC patients will also be discussed.

Learning Objectives

The target audience for this activity includes pharmacists. Upon completion
of this activity, participants will be able to:

Describe the epidemiology, risk factors, and pathology of colorectal cancer

Faculty

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and
scientific rigor in all of its continuing education activities. Faculty must disclose
to participants the existence of any significant financial interest or any other relationship
with the manufacturer of any commercial product(s) discussed in an educational presentation.
Sal Bottiglieri does not have any relevant commercial and/or financial relationships
to disclose.

Please note: The opinions expressed in this activity should not be construed as
those of the CME/CE provider. The information and views are those of the faculty through
clinical practice and knowledge of the professional literature. Portions of this activity
may include unlabeled indications. Use of drugs and devices outside of labeling should
be considered experimental and participants are advised to consult prescribing information
and professional literature.

CE Accreditation

Release Date: 03-06-2017
Expiration Date: 03-06-2020

Pharmacists

This CE activity is jointly provided by ProCE, Inc. and the National
Association of Specialty Pharmacy (NASP). ProCE is accredited by the Accreditation
Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE
Universal Activity Number 0221-9999-19-093-H01-P has been assigned to this knowledge-based,
home-study activity. This CE activity is approved for 1.25 contact hour (0.125
CEU) in states that recognize ACPE providers. Completion of an evaluation and post-test
with a score of 70% or higher is required to receive CE credit. Proof of completion
will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Funding

No external support has been received for this activity.

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.